<DOC>
	<DOCNO>NCT01717664</DOCNO>
	<brief_summary>The investigator hypothesize Mycobacterium avium paratuberculosis positive Relapsing Remitting MS subject great response Interferon beta-1a therapy plus RHB-104 Interferon beta-1a alone .</brief_summary>
	<brief_title>Proof Concept Study RHB-104 Add-On Therapy Interferon Beta-1a Relapsing Remitting Multiple Sclerosis ( RRMS )</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<mesh_term>Interferon beta-1a</mesh_term>
	<criteria>Males female age ≥18 year Signed fully inform consent provide per protocol willing comply require scheduled assessment protocol . Diagnosis relapsingremitting multiple sclerosis ( McDonald Criteria ( 2010 ) ) dissemination time space . Currently treat stable dose Rebif® , Avonex® minimum 3 month duration prior screen visit . Active MS history least one flare within past 12 month two flare past 24 month prior screen . An Expanded Disability Status Scale ( EDSS ) 6.0 less screen visit . White blood cell count ≥ 3.5x109 . Subject agree use barrier contraceptive method ( i.e . diaphragm , cervical cap , contraceptive sponge condom ) spermicidal foam/gel/cream/suppository , IUD study enrolment 6 week last dose study medication , unless subject postmenopausal otherwise incapable become pregnant reason surgery tubal ligation , vasectomy . Subject agree appropriate contraception method though completion study . Treatment biological therapy include limited Interferon beta1b , natalizumab , antiTNF biologic agent , agent intend reduce TNF ≤ 8 week prior screen within 5 halflives agent prior screening , whichever longer . Previous treatment rifabutin and/or clofazimine . Previous treatment amiodarone . Oral parenteral antibiotic 4 week prior screen . ( Topical antibiotic permit . ) Use Methylprednisolone sodium succinate , prednisone , corticosteroid 30 day prior screen . Relapse within 30 day prior screen , screen baseline . Initiation dose modification 4aminopyridine within 60 day screen . Use azathioprine , 6mercaptopurine ( 6MP ) , methotrexate , cyclosporine mycophenolate ( CellCept ) within 8 week prior screen . Use glatiramer acetate , cyclophosphamide , plasma exchange within 12 week prior screen . Use mitoxantrone within one year prior screen . Any previous treatment cladribine , T cell vaccine , alter peptide ligand . Previous total body irradiation total lymphoid irradiation . Treatment medication cause QT prolongation Torsades de Pointes within 7 day prior initiation study drug , include limited : Cisapride , pimozide , astemizole , terfenadine , ergotamine , dihydroergotamine , quinidine , procainamide , disopyramide , sotalol , ibutilde , dofetilide , dronedarone , ondansetron 5HT3 receptor agonist , citalopram dose great 20 mg/day , tolteridine quinine . Treatment follow medication within 7 day prior initiation study drug : colchicine , roflumilast , apixabin , latuda , nefazodone , buspirone , fluvoxamine , simvastatin , lovastatin , atorvastatin , amlodipine , diltiazem , felodipine , nifedipine , nitrendipine , nisoldipine , fluconazole , ketoconazole , voriconazole , St. Johns wort , grapefruit juice , antiretroviral agent , alprazolam , alfentanyl , aprepitant , aripiprazole , cyclosporine , boceprevir , carbamazepine , haloperidol , digoxin , propranolol , carvedilol , metoprolol , estrogens . Adverse reaction hypersensitivity study drug medication relate study drug . Clinically significant abnormality hematology chemistry screening confirm repeat test base investigator 's discretion , include limited , elevation great 2 time upper limit normal Aspartate Aminotransferase ( AST ) , Alanine Aminotransferase ( ALT ) , creatinine clearance le 60 ml/min screening . Serum potassium , magnesium calcium outside normal reference range consider clinically significant investigator . Positive stool result C. difficile . A positive serology Hepatitis B , Hepatitis C HIV screen except follow : If positive history previously treat Hepatitis C , HCV PCR undetectable medication least 6 month prior screen , treat hepatologist infectious disease specialist believe subject cure subject may enrol One following : History atypical mycobacterial infection ( MAP ) . History active tuberculosis ( TB ) require treatment past 3 year . Tuberculosis infection determine positive diagnostic TB test result ( define positive indeterminate ( two independent test ) quantiFERON TB Test Gold test ) . Currently diagnosed history uveitis confirm either ophthalmologist optometrist . Any evidence significant hematological , hepatic , renal , cardiac , pulmonary , metabolic , thyroid , neurological psychiatric disease might interfere subject 's ability safely enter complete study requirement . History malignancy within past five year except basal cell carcinoma skin carcinoma situ cervix treat evidence recurrence . Males use barrier contraceptive method ( i.e . condom ) spermicidal foam/gel/cream/suppository vasectomy . Females : 1. positive pregnancy test 2. lactating Refusal sign study inform consent form . Inability adequately communicate investigator respective designee and/or comply requirement entire study . History drug alcohol abuse within past 3 year . Participation experimental drug protocol within 12 week date screening . Cardiac pacemaker type metal implant contraindication MRI ( include know allergy gadolinium ) . QTc great 440ms , bundle branch block , major ST T wave abnormality make assessment QT impossible . History unstable cardiac syndrome include unstable angina , coronary artery bypass graft , myocardial infarction coronary stenting within 2 month screen ; NYHA Class 34 CHF ; history ventricular tachycardia , ventricular fibrillation , personal family history sudden death , Long QT Syndrome , Torsade de Pointes ; HR &lt; 50BPM ; take Class 1 Class 3 antiarrhythmic medication medicine know prolong QT interval associate Torsade de Pointes . Treatment medical cannabis 4 week prior screen .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Relapsing Remitting Multiple Sclerosis</keyword>
	<keyword>MAP</keyword>
	<keyword>antibiotic</keyword>
	<keyword>Interferon beta 1-a</keyword>
	<keyword>MS</keyword>
	<keyword>MRI</keyword>
	<keyword>EDSS</keyword>
	<keyword>relapse rate</keyword>
</DOC>